What does this research mean for the field?

Achieving BMI <25 kg/m2 with tirzepatide was associated with a 39.4% reduction in predicted atherosclerotic cardiovascular disease (ASCVD) risk compared to a 10.6% reduction in participants with BMI ≥25 kg/m2. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.SUPPORTS_CONSENSUS.

What question did this study set out to answer?

The study investigates the relationship between achieving a BMI below 25 kg/m2 and predicted atherosclerotic cardiovascular disease risk in individuals with obesity or overweight.

January 9, 2026EClinicalMedicineOpen Access

Achieving BMI <25 kg/m2 was associated with reduced predicted risk of atherosclerotic cardiovascular disease in people with obesity or overweight on tirzepatide or placebo: a post hoc analysis of SURMOUNT-1, -3, and -CN

Q: What are the key findings of this study?

Achieving BMI <25 kg/m2 with tirzepatide was associated with a 39.4% reduction in predicted ASCVD risk compared to a 10.6% reduction in BMI ≥25 kg/m2 participants.

Q: What does this research mean for the field?

Achieving BMI <25 kg/m2 with tirzepatide was associated with a 39.4% reduction in predicted atherosclerotic cardiovascular disease (ASCVD) risk compared to a 10.6% reduction in participants with BMI ≥25 kg/m2. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.SUPPORTS_CONSENSUS.

Q: What question did this study set out to answer?

The study investigates the relationship between achieving a BMI below 25 kg/m2 and predicted atherosclerotic cardiovascular disease risk in individuals with obesity or overweight.

View Full Paper

Ask AI

Bookmark

Key result

Achieving BMI <25 kg/m2 with tirzepatide was associated with a 39.4% reduction in predicted ASCVD risk compared to a 10.6% reduction in BMI ≥25 kg/m2 participants.

Authors

LGLixin Guo SDShan Ding WWWeihao Wang

Discussion

Member takes

Overview

Post hoc analysis shows lower predicted ASCVD risk in individuals with BMI <25 on tirzepatide, indicating important cardiovascular benefits.

Key Points

The study investigates the relationship between achieving a BMI below 25 kg/m2 and predicted atherosclerotic cardiovascular disease risk in individuals with obesity or overweight.
Analyzed pooled individual-level data from participants in SURMOUNT-1, -3, and -CN trials.
Calculated 10-year ASCVD risk using American College of Cardiology/American Heart Association equations.
Used a mixed model for repeated measures to compare changes in ASCVD risk by BMI group.
495 participants (18.4%) achieved BMI <25 kg/m2 by trial end.
Those achieving BMI <25 kg/m2 had a 39.4% reduction in predicted ASCVD risk compared to 10.6% in the BMI ≥25 kg/m2 group (P < 0.001).
Greater improvements in blood pressure and lipids were observed in the BMI <25 kg/m2 group (P < 0.001).

Cite This Study

Guo et al. (2025) studied this question. Achieving BMI <25 kg/m2 with tirzepatide was associated with a 39.4% reduction in predicted ASCVD risk compared to a 10.6% reduction in BMI ≥25 kg/m2 participants.

synapsesocial.com/papers/696128f244c2cd6c68456c81 https://doi.org/10.1016/j.eclinm.2025.103722

View Full Paper

Ask AI

Bookmark

January 9, 2026EClinicalMedicineOpen Access

Achieving BMI <25 kg/m2 was associated with reduced predicted risk of atherosclerotic cardiovascular disease in people with obesity or overweight on tirzepatide or placebo: a post hoc analysis of SURMOUNT-1, -3, and -CN

View Full Paper

Ask AI

Bookmark

Key result

Achieving BMI <25 kg/m2 with tirzepatide was associated with a 39.4% reduction in predicted ASCVD risk compared to a 10.6% reduction in BMI ≥25 kg/m2 participants.

Authors

LGLixin Guo SDShan Ding WWWeihao Wang

Discussion

Member takes

Overview

Post hoc analysis shows lower predicted ASCVD risk in individuals with BMI <25 on tirzepatide, indicating important cardiovascular benefits.

Key Points

The study investigates the relationship between achieving a BMI below 25 kg/m2 and predicted atherosclerotic cardiovascular disease risk in individuals with obesity or overweight.
Analyzed pooled individual-level data from participants in SURMOUNT-1, -3, and -CN trials.
Calculated 10-year ASCVD risk using American College of Cardiology/American Heart Association equations.
Used a mixed model for repeated measures to compare changes in ASCVD risk by BMI group.
495 participants (18.4%) achieved BMI <25 kg/m2 by trial end.
Those achieving BMI <25 kg/m2 had a 39.4% reduction in predicted ASCVD risk compared to 10.6% in the BMI ≥25 kg/m2 group (P < 0.001).
Greater improvements in blood pressure and lipids were observed in the BMI <25 kg/m2 group (P < 0.001).

Cite This Study

synapsesocial.com/papers/696128f244c2cd6c68456c81 https://doi.org/10.1016/j.eclinm.2025.103722

View Full Paper

Ask AI

Bookmark